LBA4_PRNivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

Abstract Background Part 1 of CheckMate 227 (NCT02477826), a phase III study in 1L NSCLC, has dual primary endpoints. The primary endpoint of progression-free survival (PFS) with NIVO + IPI vs chemo in patients (pts) with tumor mutational burden ≥ 10 mut/Mb was met, as reported previously. Here we p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser:	Peters, S, Ramalingam, S S, Paz-Ares, L, Bernabe Caro, R, Zurawski, B, Kim, S-W, Alexandru, A, Lupinacci, L, de la Mora Jimenez, E, Sakai, H, Albert, I, Vergnenegre, A, Reck, M, Borghaei, H, Brahmer, J R, O’Byrne, K J, Geese, W J, Bhagavatheeswaran, P, Nathan, F E, Hellmann, M D
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!